|Bid||11.44 x 1100|
|Ask||29.99 x 1000|
|Day's Range||28.30 - 29.61|
|52 Week Range||16.74 - 49.10|
|Beta (5Y Monthly)||1.01|
|PE Ratio (TTM)||31.74|
|Earnings Date||Aug 03, 2022 - Aug 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||57.20|
Subscribe to Yahoo Finance Plus to view Fair Value for RCUS
Most readers would already be aware that Arcus Biosciences' (NYSE:RCUS) stock increased significantly by 40% over the...
HAYWARD, Calif., June 24, 2022--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted ten new employees options to purchase a total of 22,850 shares of the Company’s common stock at an exercise price per share of $24.98, which was the closing price on June 23, 2022, and restricted stock units to acquire a total of 11,425 shares
HAYWARD, Calif., May 31, 2022--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 43rd Annual Global Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, California. The fireside chat will take place on Thursday, June 16th, 2022 at 9:20 a.m. PT.